FDA calls for investigation into controversial Alzheimer's drug approval
Published
The FDA is calling for an independent watchdog to investigate how staff interacted with Biogen in the run-up to the approval of Aduhelm.
Full ArticlePublished
The FDA is calling for an independent watchdog to investigate how staff interacted with Biogen in the run-up to the approval of Aduhelm.
Full ArticleThe FDA chief, Janet Woodcock, M.D., has requested for an investigation of Biogen's Alzheimer's drug after recognizing a..
The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer,..